Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of recMAGE-A3 + AS15 in MAGE-A3-positive metastatic cutaneous melanoma
2008-001301-42Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recMAGE-A3 + AS15 in cutaneous melanoma (CM), sponsored by GSK. Primary endpoints: Clinical activity and Safety. Started Nov 2008; status: completed.
02
Drugs
recMAGE-A3 + AS15
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2008-001301-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001301-42.